



AP32573-AAA 072396.0237
PATENT

0360/05/03/02
#8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Robbins et al.
Serial No. : 10/075,869 Examiner: To Be Assigned
Filed : February 13, 2002 Group Art Unit: To Be Assigned
For : IDENTIFICATION OF PEPTIDES THAT FACILITATE UPTAKE AND
CYTOPLASMIC AND/OR NUCLEAR TRANSPORT OF PROTEINS,
DNA AND VIRUSES

INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States
Postal Service as first class mail in an envelope addressed to: Assistant
Commissioner for Patents, Washington, D.C. 20231

August 28, 2002
Date of Deposit

Alicia A. Russo
Attorney Name

46,192
Registration No.

Alicia A. Russo
Signature

August 28, 2002
Date of Signature

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§1.97 and 1.98, Applicants respectfully request
that the references relating to the above-mentioned application listed herein in reverse
chronological order be made of record in the U.S. Patent and Trademark Office.

The referenced citations are also listed in the accompanying PTO Form-
1449 and copies of the references are provided. A copy of the International Search
Report for corresponding PCT application no. PCT/US00/24034 is also enclosed.

1. United States Patent No. 6,221,355 by Dowdy, filed December 10, 1998, issued April 24, 2001.
2. United States Patent No. 6,184,038 by O'Hare et al., filed January 26, 1998, issued February 6, 2001.
3. International Application No. PCT/US00/23440/23440, by Cellgate, Inc., Rothbard et al., inventors, published March 1, 2001 as WO 01/13957.
4. Mai et al. "A Proapoptotic Peptide for the Treatment of Solid Tumors", 2001, *Cancer Res*, 61:7709-7712.
5. Mathis et al. " β -cell death during progression to diabetes," 2001 *Nature* 414:792.
6. International Application No. PCT/US00/05097, by Washington University, Dowdy, inventor, published October 19, 2000 as WO 00/62067.
7. United States Patent No. 6,017,735 by O'Hare et al., filed January 26, 1998, issued January 25, 2000.
8. Mi et al., "Characterization of a Class of Cationic Peptides Able to Facilitate Efficient Protein Transduction *in Vitro* and *in Vivo*", 2000, *Mol Ther*, 2:339-47.
9. Schwarze and Dowdy, "*In vivo* protein transduction: intracellular delivery of biologically active proteins, compounds and DNA", 2000, *TIPS* 21: 45-48.
10. Elliot and O'Hare, "Cytoplasm-to-Nucleus Translocation of a Herpesvirus Tegument Protein during Cell Division", 2000, *J. Virol.* 74: 2131-2141.
11. International Application No. PCT/US99/09028, by Washington University, Dowdy, inventor, published November 4, 1999 as WO 99/55899.

12. European Patent Application No. 98105625.2, by Biogen, Inc., Barsoum et al., inventors, published March 24, 1999, as EP 0 903 408 A2.

13. International Application No. PCT/GB98/02269, by Selective Genetics, Inc., Larocca, inventor, published March 4, 1999 as WO 99/10485.

14. International Application No. PCT/US98/17949, by The University Court of the University of Glasgow, Allen et al., inventors, published February 11, 1999 as WO 99/06542.

15. Branden et al., "A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA", 1999, *Nat. Biotechnol.* 17: 784-787.

16. Brown & Wouters, "A poposis, p53, and Tumor Cell Sensitivity to Anticancer Agents", 1999, *Cancer Res.* 59: 1391-1399.

17. Derer et al., "Direct protein transfer to terminally differentiated muscle cells", 1999, *J. Mol. Med.* 77: 609-613.

18. Ellerby et al., "Anti-cancer activity of targeted pro-apoptotic peptides", 1999, *Nat. Med.* 5: 1032.

19. Gambotto et al., "Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12", 1999, *Cancer Gene Ther.* 6: 45.

20. Hiroshi et al., "Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established timor in poorly immunogenic tumor models", 1999, *Gene Ther.* 6: 1988.

21. Huttner et al., "Antimicrobial peptides as mediators of epithelial host defense," 1999, *Ped. Res.* 45:785.

22. Ivanenkov et al., "Targeted delivery of multivalent phage display vectors into mammalian cells," 1999, *Biochem. et Biophys. Acta* 1448: 463-472.

23. Ivanenkov et al., "Uptake and intracellular fate of phage display vectors in mammalian cells", 1999, *Biochem. et Biophys. Acta* 1448: 450-462.

24. Kim et al., "Adoptive-transfer therapy of tumors with the tumor-specific primary cytotoxic T cells induced in vitro with B7.1-transduced MCA205 cell line", 1999, *Cancer Immunol. Immunother.* 47: 257.

25. Osaki et al., "Potent antitumor effects mediated by local expression of the mature form of the interferon- γ inducing factor, interleukin-18 (IL-18)", 1999, *Gene Ther.* 6: 808.

26. Pittenger et al., "Multilineage Potential of Adult Human Mesenchymal Stem Cells", 1999, *Science* 284: 143.

27. Nishioka et al., "Induction of Systemic and Therapeutic Antitumor Immunity Using Intratumoral Injection of Dendritic Cells Genetically Modified to Express Interleukin 12¹", 1999, *Cancer Res.* 59: 4035.

28. Schwarze et al., "In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse", 1999, *Science* 285: 1569-1572.

29. Vocero-Akbani et al., "Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein", 1999, *Nat. Med.* 5: 29-33.

30. Yamabe et al., "Cancer gene therapy using a pro-apoptotic gene, caspase-3", 1999, *Gene Ther.* 6: 1952-1959.

31. United States Patent No. 5,804,604 by Frankel, filed May 25, 1995, issued September 8, 1998.

32. International Application No. PCT/US98/10079, by Cytogen Corp., and Elan Corp., PLC, O'Mahony et al, inventors, published November 19, 1998 as WO 98/51825.
33. International Application No. PCT/US98/10088, by Cytogen Corp., and Elan Corp., PLC, Alvarez et al, inventors, published November 19, 1998 as WO 98/51325.
34. Derossi et al., "Trojan peptides: the penetratin system for intracellular delivery", 1998, *Trends in Cell Biol.* 8: 84-87.
35. Ghivizzani et al., "Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor α soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects", 1998, *Proc. Natl. Acad. Sci. USA* 95: 4613.
36. Mangeney and Heidmann, "Tumor cells expressing a retroviral envelope escape immune rejection *in vivo*", 1988, *Proc. Natl. Acad. Sci. USA* 95: 14920.
37. Nagahara et al., "Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27^{Kip1} induces cell migration", 1998, *Nat. Med.* 4: 1449-1452.
38. Noffz et al., "Neutrophils but Not Eosinophils Are Involved in Growth Suppression of IL-4-Secreting Tumors¹", 1988, *J. Immunol.* 160: 345.
39. Osaki et al., "IFN- γ -Inducing Factor/IL-18 Administration Mediates IFN- γ - and IL-12-Independent Antitumor Effects¹", 1998, *J. Immunol.* 160: 1742.
40. Sakai et al., "Potential Withdrawal of Rheumatoid Synovium by the Induction of Apoptosis Using a Novel *in Vivo* Model of Rheumatoid Arthritis", 1998, *Arthritis Rheum.* 41:1251-1257.
41. Villaverde et al., "A Cell Adhesion Peptide from Foot-and-Mouth Disease Virus Can Direct Cell Targeted Delivery of a Functional Enzyme", 1998, *Biotechnol. and Bioeng.* 59: 294-301.

42. Wakisaka et al., "Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA)", 1998, *Clin. Exp. Immunol.* 114: 119-128.
43. Cayeux et al., "Influence of Gene-Modified (IL-7, IL-4, and B7) Tumor Cell Vaccines on Tumor Antigen Presentation¹", 1997, *J. Immunol.* 158: 2834.
44. Elliot and O'Hare, "Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein", 1997, *Cell* 188: 223-233.
45. Felgner, "Nonviral Strategies for Gene Therapy", 1997, *Sci. Am.* 276: 102-106.
46. Ghivizzani et al., "Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: implications for arthritis gene therapy", 1997, *Gene Ther.* 4: 977.
47. Ghivizzani et al., "Constitutive Intra-Articular Expression of Human IL-1 β Following Gene Transfer to Rabbit Synovium Produces All Major Pathologies of Human Rheumatoid Arthritis¹", 1997, *J. Immunol.* 159: 3604.
48. Kato and Sugiyama, "Targeted Delivery of Peptides, Proteins, and Genes by Receptor-Mediated Endocytosis", 1997, *Crit. Rev. Ther. Drug Carrier Syst.* 14: 287-331.
49. Kirpotin et al., "Sterically Stabilized Anti-HER2 Immunoliposomes: Design and Targeting to Human Breast Cancer Cells *in Vitro*", 1997, *Biochemistry* 36: 66-75.
50. Knudsen and Nielsen, "Application of peptide nucleic acid in cancer therapy", 1997, *Anticancer Drugs* 8: 113-118.
51. Spragg et al., "Immunotargeting of liposomes to activated vascular endothelial cells: A strategy for site-selective delivery in the cardiovascular system", 1997, *Proc. Natl. Acad. Sci. USA* 94: 8795-8800.

52. Szardenings et al., "Phage Display Selection on Whole Cells Yields a Peptide Specific for Melanocortin Receptor 1", 1997, *J. Biol. Chem.* 272: 27943-27948.
53. Vives et al., "A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus", 1997, *J. Biol. Chem.* 272: 16010-16017.
54. Barry and Johnson, "Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries", 1996, *Nat. Med.* 2: 299-305.
55. Berlose et al., "Conformational and associative behaviours of the third helices of antennapedia homeodomain in membrane-mimetic environments", 1996, *Eur. J. Biochem.* 242: 372.
56. Derossi et al., "Cell Internalization of the Third Helix of the Antennapedia Homeodomain Is Receptor-independent", 1996, *J. Biochem.* 217: 18188-18193.
57. Douglas et al., "Targeted gene delivery by tropism-modified adenoviral vectors", 1996, *Bio/Technology* 14:1574-1578.
58. Fitzgerald, "Why toxins!" 1996, *Semin. Cancer Biol.* 7: 87-95.
59. Moy et al., "Tat-Mediated Protein Delivery Can Facilitate MHC Class I Presentation of Antigens", 1996, *Mol. Biotechnol.* 6: 105-113.
60. Nita et al., "Direct Gene Delivery to Synovium", 1996, *Arthritis Rheum.* 39: 820.
61. Ohno et al., "Adoptive Immunotherapy with Tumor-Specific T Lymphocytes Generated from Cytokine Gene-Modified Tumor-Primed Lymph Node Cells¹", 1996, *J. Immunol.* 156: 3875.

62. Sato et al., "Importance of receptor-mediated endocytosis in peptide delivery and targeting: kinetic aspects", 1996, *Adv. Drug Deliv. Rev.* 19: 445-467.
63. Shen et al., "(C) Means to Enhance Penetration: (3) Enhancement of polypeptide and protein absorption by macromolecular carriers via endocytosis and transcytosis", 1992, *Adv. Drug Deliv. Rev.*, 8:93-113.
64. Zeigler et al., "Molecular conjugate-mediated Gene Transfer Into Isolated Human Kidneys", 1996, *Transplantation* 61: 812-817.
65. Wickham et al., "Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs", 1995, *Gene Ther.* 2: 750-756.
66. Berns and Giraud, "Adenovirus and Adeno-Associated Virus as Vectors for Gene Therapy", 1995, *Ann. N. Y. Acad. Sci.* 772: 95-104.
67. Haneberg et al., "The Colon and Rectum as Inductor Sites for Local and Distant Mucosal Immunity", 1995, *Adv. Exp. Med. Biol.* 371A: 107-109.
68. Smith, "Viral Vectors in Gene Therapy", 1995, *Ann. Rev. Microbiol.* 49: 807-838.
69. Yang et al., "Cellular and Humoral Immune Responses to Viral Antigens Create Barriers to Lung-Directed Gene Therapy with Recombinant Adenoviruses", 1995, *J. Virol.* 69: 2004-2015.
70. United States Patent No. 5,338,665 by Schatz, filed October 15, 1992, issued August 16, 1994.
71. Fawell et al., "Tat-mediated delivery of heterologous proteins into cells", 1994, *Proc. Natl. Acad. Sci. USA* 91: 664-668.

72. Kuzel and Rosen, "Antibodies in the treatment of human cancer", 1994, *Curr. Opin. Oncol.* 6: 622-626.
73. Sreerama and Woody, "Poly(Pro)II in Helices in Globular Proteins: Identification and Circular Dichroic Analysis", 1994, *Biochemistry* 33: 10022-10025.
74. Weitzman et al., "Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA", 1994, *Proc. Natl. Acad. Sci. USA* 91: 5808-5812.
75. Kozarsky and Wilson, "Gene therapy: adenovirus vectors", 1993, *Curr. Opin. Genet. Dev.* 3: 49-50.
76. Miller et al., "Biology of Disease: Mucosal Immunity, HIV Transmission, and AIDS" 1993, *Lab Invest.* 68: 129-145.
77. Mulligan, "The Basic Science of Gene Therapy", 1993, *Science* 260: 926-932.
78. Vitetta et al., "Immunotoxins: magic bullets or misguided missiles?", 1993, *Immunol. Today* 14: 252-259.
79. Wu and Wu, "Liver-directed gene delivery", 1993, *Adv. Drug Deliv. Rev.* 12:159-167.
80. Zatloukal et al., "Domestic gene therapy for cancer: the utility of transferrin infection in generating 'tumor vaccines'", 1993, *Gene* 135: 199-207.
81. Wagner et al., "Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Toward a synthetic virus-like gene-transfer vehicle", 1992, *Proc. Natl. Acad. Sci.* 89: 6099-6103.

82. Wagner et al., "Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes", 1992, *Proc. Natl. Acad. Sci.* 89: 7934-7938.
83. Evans, "The Role of Proteinases in Cartilage Destruction", 1991, *Agents Actions Suppl.* 32: 135-152.
84. Curiel et al., "Adenovirus enhancement of transferrin-polylysine-mediated gene delivery", 1991, *Proc. Natl. Acad. Sci.* 88: 8850-8854.
85. Basu, "Receptor-Mediated Endocytosis of Macromolecular Conjugates in Selective Drug Delivery", 1990, *Biochem. Pharmacol.* 40: 1941-1946.
86. Wu and Wu, "Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements *in Vivo*", 1989, *J. Biol. Chem.* 264: 16985-16987.
87. Frankel and Pabo, "Cellular Uptake of the Tat Protein from Human Immunodeficiency Virus", 1988, *Cell* 55: 1189-1193.
88. Green and Lowenstein, "Autonomous Functional Domains of Chemically Synthesizes Human Immunodeficiency Virus Tat *Trans*-Activator Protein", 1988, *Cell* 55: 1179-1188.
89. Wu and Wu, "Receptor-mediated Gene Delivery and Expression *in Vivo*", 1988, *J. Biol. Chem.* 263: 14621-14624.
90. Wu and Wu, "Receptor-mediated *in Vivo* Gene Transformation by a Soluble DNA Carrier System", 1987, *J. Biol. Chem.* 262: 4429-4432.

91. Bayer et al., "Preparation of Ferritin-Avidin Conjugates by Reductive Alkylation for Use in Electron Microscopic Cytochemistry", 1976, *Histchem. Cytochem.* 24: 933-939.


Identification of the above-listed references is not to be construed as an admission by the Applicants or the attorneys of the Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the above-mentioned application.

No fee is believed to be required in connection with this communication. However, if a fee is required, the Commissioner is hereby authorized to charge the fee to Deposit Account No. 02-4377. A copy of this sheet is enclosed.

Respectfully submitted,

Dated: August 28, 2002



Rochelle K. Seide
Patent Office Reg. No. 32,300

Alicia A. Russo
Patent Office Reg. No. 46,192

Attorneys for Applicants
(212) 408-2627

91. Bayer et al., "Preparation of Ferritin-Avidin Conjugates by Reductive Alkylation for Use in Electron Microscopic Cytochemistry", 1976, *Histochem. Cytochem.* 24: 933-939.


Identification of the above-listed references is not to be construed as an admission by the Applicants or the attorneys of the Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the above-mentioned application.

No fee is believed to be required in connection with this communication. However, if a fee is required, the Commissioner is hereby authorized to charge the fee to Deposit Account No. 02-4377. A copy of this sheet is enclosed.

Respectfully submitted,

Dated: August 28, 2002



Rochelle K. Seide
Patent Office Reg. No. 32,300

Alicia A. Russo
Patent Office Reg. No. 46,192

Attorneys for Applicants
(212) 408-2627

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32573-AAA 072396.0237

Serial No.
10/075,869

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Robbins et al.

Filing Date
February 13, 2002

Group
TBA

U.S. PATENT DOCUMENTS

*Exam. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate
	6 2 2 1 3 5 5	4/24/01	Dowdy	424	192.1	
	6 1 8 4 0 3 8	2/6/01	O'Hare et al.	435	455	
	6 0 1 7 7 3 5	1/25/00	O'Hare et al.	435	69.7	
	5 8 0 4 6 0 4	9/8/98	Frankel	530	324	
	5 3 3 8 6 6 5	8/16/94	Schatz	435	6	

FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Class	SubClass	Translator Yes No
0 1 1 3 9 5 7	3/1/01	WIPO			
0 0 6 2 0 6 7	10/19/00	WIPO			
9 9 5 5 8 9 9	11/4/99	WIPO			
0 9 0 3 4 0 8	3/24/99	Europe			
9 9 1 0 4 8 5	3/4/99	WIPO			
9 9 0 6 5 4 2	2/11/99	WIPO			
9 8 5 1 8 2 5	11/19/98	WIPO			
9 8 5 1 3 2 5	11/19/98	WIPO			

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

	Mai et al. "A Proapoptotic Peptide for the Treatment of Solid Tumors", 2001, <i>Cancer Res</i> , 61:7709-7712.
	Mathis et al. " β -cell death during progression to diabetes," 2001 <i>Nature</i> 414:792.
	Mi et al., "Characterization of a Class of Cationic Peptides Able to Facilitate Efficient Protein Transduction

NY02:403374.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32573-AAA 072396.0237

Serial No.
10/075,869

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

SEP 03 2002 (Use several sheets if necessary)

Applicant
Robbins et al.

Filing Date
February 13, 2002

Group
TBA

☐ *in Vitro and in Vivo*", 2000, *Mol Ther*, 2:339-47.

☐ Schwarze and Dowdy, "*In vivo* protein transduction: intracellular delivery of biologically active proteins, compounds and DNA", 2000, *TIPS* 21: 45-48.

☐ Elliot and O'Hare, "Cytoplasm-to-Nucleus Translocation of a Herpesvirus Tegument Protein during Cell Division", 2000, *J. Virol.* 74: 2131-2141.

☐ Branden et al., "A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA", 1999, *Nat. Biotechnol.* 17: 784-787.

☐ Brown & Wouters, "A poptosis, p53, and Tumor Cell Sensitivity to Anticancer Agents", 1999, *Cancer Res* 59: 1391-1399.

☐ Derer et al., "Direct protein transfer to terminally differentiated muscle cells", 1999, *J. Mol. Med.* 77: 609-613.

☐ Ellerby et al., "Anti-cancer activity of targeted pro-apoptotic peptides", 1999, *Nat. Med.* 5: 1032.

☐ Gambotto et al., "Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12", 1999, *Cancer Gene Ther.* 6: 45.

☐ Hiroshi et al., "Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models", 1999, *Gene Ther.* 6: 1988.

☐ Huttner et al., "Antimicrobial peptides as mediators of epithelial host defense," 1999, *Ped. Res.* 45:785.

☐ Ivanenkov et al., "Targeted delivery of multivalent phage display vectors into mammalian cells," 1999, *Biochem. et Biophys. Acta* 1448: 463-472.

☐ Ivanenkov et al., "Uptake and intracellular fate of phage display vectors in mammalian cells", 1999, *Biochem. et Biophys. Acta* 1448: 450-462.

☐ Kim et al., "Adoptive-transfer therapy of tumors with the tumor-specific primary cytotoxic T cells induced in vitro with B7.1-transduced MCA205 cell line", 1999, *Cancer Immunol. Immunother.* 47: 257.

☐ Osaki et al., "Potent antitumor effects mediated by local expression of the mature form of the interferon- γ inducing factor, interleukin-18 (IL-18)", 1999, *Gene Ther.* 6: 808.

☐ Pittenger et al., "Multilineage Potential of Adult Human Mesenchymal Stem Cells", 1999, *Science* 284: 143.

NY02:403374.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32573-AAA 072396.0237

Serial No.
10/075,869



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant
Robbins et al.

Filing Date
February 13, 2002

Group
TBA

Nishioka et al., "Induction of Systemic and Therapeutic Antitumor Immunity Using Intratumoral Injection of Dendritic Cells Genetically Modified to Express Interleukin 12¹", 1999, *Cancer Res.* 59: 4035.

Schwarze et al., "In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse" 1999, *Science* 285: 1569-1572.

Vocero-Akbani et al., "Killing HIV-infected cells by transduction with an HIV protease-activated caspase 3 protein", 1999, *Nat. Med.* 5: 29-33.

Yamabe et al., "Cancer gene therapy using a pro-apoptotic gene, caspase-3", 1999, *Gene Ther.* 6: 1952-1959.

Derossi et al., "Trojan peptides: the penetratin system for intracellular delivery", 1998, *Trends in Cell Biol* 8: 84-87.

Ghivizzani et al., "Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor α soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects", 1998, *Proc. Natl. Acad. Sci. USA* 95: 4613.

Mangeney and Heidmann, "Tumor cells expressing a retroviral envelope escape immune rejection *in vivo*" 1988, *Proc. Natl. Acad. Sci. USA* 95: 14920.

Nagahara et al., "Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27^{Kip1} induces cell migration", 1998, *Nat. Med.* 4: 1449-1452.

Noffz et al., "Neutrophils but Not Eosinophils Are Involved in Growth Suppression of IL-4-Secreting Tumors¹", 1988, *J. Immunol.* 160: 345.

Osaki et al., "IFN- γ -Inducing Factor/IL-18 Administration Mediates IFN- γ - and IL-12-Independent Antitumor Effects¹", 1998, *J. Immunol.* 160: 1742.

Sakai et al., "Potential Withdrawal of Rheumatoid Synovium by the Induction of Apoptosis Using a Novel *In Vivo* Model of Rheumatoid Arthritis", 1998, *Arthritis Rheum.* 41:1251-1257.

NY02:403374.1

Examiner


Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32573-AAA 072396.0237

Serial No.
10/075,869



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Robbins et al.

Filing Date
February 13, 2002

Group
TBA

- | | | |
|--|--|---|
| | | Villaverde et al., "A Cell Adhesion Peptide from Foot-and-Mouth Disease Virus Can Direct Cell Targeted Delivery of a Functional Enzyme", 1998, <i>Biotechnol. and Bioeng.</i> 59: 294-301. |
| | | Wakisaka et al., "Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA)", 1998, <i>Clin. Exp. Immunol.</i> 114: 119-128 |
| | | Cayeux et al., "Influence of Gene-Modified (IL-7, IL-4, and B7) Tumor Cell Vaccines on Tumor Antigen Presentation ¹ ", 1997, <i>J. Immunol.</i> 158: 2834. |
| | | Elliot and O'Hare, "Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein", 1997, <i>Cell</i> 188: 223-233. |
| | | Felgner, "Nonviral Strategies for Gene Therapy", 1997, <i>Sci. Am.</i> 276: 102-106. |
| | | Ghivizzani et al., "Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: implication for arthritis gene therapy", 1997, <i>Gene Ther.</i> 4: 977. |
| | | Ghivizzani et al., "Constitutive Intra-Articular Expression of Human IL-1 β Following Gene Transfer to Rabbit Synovium Produces All Major Pathologies of Human Rheumatoid Arthritis ¹ ", 1997, <i>J. Immunol.</i> 159: 3604. |
| | | Kato and Sugiyama, "Targeted Delivery of Peptides, Proteins, and Genes by Receptor-Mediated Endocytosis", 1997, <i>Crit. Rev. Ther. Drug Carrier Syst.</i> 14: 287-331. |
| | | Kirpotin et al., "Sterically Stabilized Anti-HER2 Immunoliposomes: Design and Targeting to Human Breast Cancer Cells <i>in Vitro</i> ", 1997, <i>Biochemistry</i> 36: 66-75. |
| | | Knudsen and Nielsen, "Application of peptide nucleic acid in cancer therapy", 1997, <i>Anticancer Drugs</i> 8: 113-118. |
| | | Spragg et al., "Immunotargeting of liposomes to activated vascular endothelial cells: A strategy for site-selective delivery in the cardiovascular system", 1997, <i>Proc. Natl. Acad. Sci. USA</i> 94: 8795-8800. |

NY02:403374.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32573-AAA 072396.0237

Serial No.
10/075,869


Applicant
Robbins et al.

Filing Date
February 13, 2002

Group
TBA

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)



Szardenings et al., "Phage Display Selection on Whole Cells Yields a Peptide Specific for Melanocortin Receptor 1", 1997, *J. Biol. Chem.* 272: 27943-27948.

Vives et al., "A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus", 1997, *J. Biol. Chem.* 272: 16010-16017.

Barry and Johnson, "Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries", 1996, *Nat. Med.* 2: 299-305.

Berlose et al., "Conformational and associative behaviours of the third helices of antennapedia homeodomain in membrane-mimetic environments", 1996, *Eur. J. Biochem.* 242: 372.

Derossi et al., "Cell Internalization of the Third Helix of the Antennapedia Homeodomain Is Receptor-independent", 1996, *J. Biochem.* 217: 18188-18193.

Douglas et al., "Targeted gene delivery by tropism-modified adenoviral vectors", 1996, *Bio/Technology* 14:1574-1578.

Fitzgerald, "Why toxins!" 1996, *Semin. Cancer Biol.* 7: 87-95.

Moy et al., "Tat-Mediated Protein Delivery Can Facilitate MHC Class I Presentation of Antigens", 1996, *Mol. Biotechnol.* 6: 105-113.

Nita et al., "Direct Gene Delivery to Synovium", 1996, *Arthritis Rheum.* 39: 820.

Ohno et al., "Adoptive Immunotherapy with Tumor-Specific T Lymphocytes Generated from Cytokine Gene-Modified Tumor-Primed Lymph Node Cells", 1996, *J. Immunol.* 156: 3875.

Sato et al., "Importance of receptor-mediated endocytosis in peptide delivery and targeting: kinetic aspects", 1996, *Adv. Drug Deliv. Rev.* 19: 445-467.

Shen et al., "(C) Means to Enhance Penetration: (3) Enhancement of polypeptide and protein absorption by macromolecular carriers via endocytosis and transcytosis", 1992, *Adv. Drug Deliv. Rev.*, 8:93-113.

NY02:403374.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32573-AAA 072396.0237

Serial No.
10/075,869

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant
Robbins et al.

Filing Date
February 13, 2002

Group
TBA

(Use several sheets if necessary)



Zeigler et al., "Molecular conjugate-mediated Gene Transfer Into Isolated Human Kidneys", 1996, *Transplantation* 61: 812-817.

Wickham et al., "Targeting of adenovirus penton base to new receptors trough replacement of its RGD motif with other receptor-specific peptide motifs", 1995, *Gene Ther.* 2: 750-756.

Berns and Giraud, "Adenovirus and Adeno-Associated Virus as Vectors for Gene Therapy", 1995, *Ann. N. Y. Acad. Sci.* 772: 95-104.

Haneberg et al., "The Colon and Rectum as Inductor Sites for Local and Distant Mucosal Immunity", 1995 *Adv. Exp. Med. Biol.* 371A: 107-109.

Smith, "Viral Vectors in Gene Therapy", 1995, *Ann. Rev. Microbiol.* 49: 807-838.

Yang et al., "Cellular and Humoral Immune Responses to Viral Antigens Create Barriers to Lung-Directed Gene Therapy with Recombinant Adenoviruses", 1995, *J. Virol.* 69: 2004-2015.

Fawell et al., "Tat-mediated delivery of heterologous proteins into cells", 1994, *Proc. Natl. Acad. Sci. USA* 91: 664-668.

Kuzel and Rosen, "Antibodies in the treatment of human cancer", 1994, *Curr. Opin. Oncol.* 6: 622-626.

Sreerama and Woody, "Poly(Pro)II in Helices in Globular Proteins: Identification and Circular Dichroic Analysis", 1994, *Biochemistry* 33: 10022-10025.

Weitzman et al., "Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA", 1994, *Proc. Natl. Acad. Sci. USA* 91: 5808-5812.

Kozarsky and Wilson, "Gene therapy: adenovirus vectors", 1993, *Curr. Opin. Genet. Dev.* 3: 49-50.

Miller et al., "Biology of Disease: Mucosal Immunity, HIV Transmission, and AIDS" 1993, *Lab Invest.* 68 129-145.

NY02:403374.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32573-AAA 072396.0237

Serial No.
10/075,869


Applicant
Robbins et al.

Filing Date
February 13, 2002

Group
TBA

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)



Mulligan, "The Basic Science of Gene Therapy", 1993, *Science* 260: 926-932.

Vitetta et al., "Immunotoxins: magic bullets or misguided missiles?", 1993, *Immunol. Today* 14: 252-259.

Wu and Wu, "Liver-directed gene delivery", 1993, *Adv. Drug Deliv. Rev.* 12:159-167.

Zatloukal et al., "Domestic gene therapy for cancer: the utility of transferrin infection in generating 'tumor vaccines'", 1993, *Gene* 135: 199-207.

Wagner et al., "Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Toward a synthetic virus-like gene-transfer vehicle", 1992, *Proc. Natl. Acad. Sci.* 89: 6099-6103.

Wagner et al., "Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes", 1992, *Proc. Natl. Acad. Sci.* 89: 7934-7938.

Evans, "The Role of Proteinases in Cartilage Destruction", 1991, *Agents Actions Suppl.* 32: 135-152.

Curiel et al., "Adenovirus enhancement of transferrin-polylysine-mediated gene delivery", 1991, *Proc. Natl. Acad. Sci.* 88: 8850-8854.

Basu, "Receptor-Mediated Endocytosis of Macromolecular Conjugates in Selective Drug Delivery", 1990, *Biochem. Pharmacol.* 40: 1941-1946.

Wu and Wu, "Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements *in Vivo*", 1989, *J. Biol. Chem.* 264: 16985-16987.

Frankel and Pabo, "Cellular Uptake of the Tat Protein from Human Immunodeficiency Virus", 1988, *Cell* 55: 1189-1193.

Green and Lowenstein, "Autonomous Functional Domains of Chemically Synthesized Human Immunodeficiency Virus Tat *Trans*-Activator Protein", 1988, *Cell* 55: 1179-1188.

NY02:403374.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32573-AAA 072396.0237

Serial No.
10/075,869

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Robbins et al.

Filing Date
February 13, 2002

Group
TBA

Wu and Wu, "Receptor-mediated Gene Delivery and Expression *in Vivo*", 1988, *J. Biol. Chem.* 263: 14621-14624.

Wu and Wu, "Receptor-mediated *in Vivo* Gene Transformation by a Soluble DNA Carrier System", 1987, *J. Biol. Chem.* 262: 4429-4432.

Bayer et al., "Preparation of Ferritin-Avidin Conjugates by Reductive Alkylation for Use in Electron Microscopic Cytochemistry", 1976, *Histochem. Cytochem.* 24: 933-939.

NY02:403374.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.